Abstract 545P
Background
Immune checkpoint inhibitors (ICI) are standard of care in advanced non-small cell lung cancer (NSCLC) without driver mutations. A small proportion of patients (pts) treated with ICIs will achieve durable responses. We describe outcomes of a real-world cohort of pts who completed two years of pembrolizumab (pembro).
Methods
Clinical data of pts who completed 35 cycles of first-line pembro for NSCLC (or 30-34 cycles with reason for cessation other than progression) was collected retrospectively from sites across Australia via the AUstralian Registry and biObank of thoRacic cAncers (AURORA). Primary endpoints were progression rate post pembro completion and progression free survival (PFS). Local treatment of oligoprogressive disease during pembro was included. Analyses were performed using R.
Results
71 pts from six centres with a median age of 66.0 yrs, 49% male & 90% ECOG≤1 were identified. Pts were Caucasian (82%) or Asian (16%); past (69%) or current (25%) smokers with a mean 37 pack year history. Histology comprised 73% adenocarcinoma, 16% squamous. 18 pts (25%) had brain mets at diagnosis, 16 treated (8 resected, 8 RT). Median PD-L1 tumour proportion score (TPS) was 68%; 12 pts (17%) PD-L1 negative, 43 pts (61%) TPS≥50%. No pts had ALK/ROS/EGFR mutations; 29/49 tested (60%) had K-Ras mutations. Median follow up from pembro start was 38.7 months (24.5 – 65.6). Table: 545P
Total population (n=71) | |||
Pembro | 39 (55%) | Median time on pembro | 24.2 mo |
Pembro + chemo | 32 (45%) | (20.0-35.3) | |
Objective Response Rate (ORR) | 78.6% | 76.9% | |
CR | 20 (29%) | ORR pembro | 80.6% |
PR | 35 (50%) | ORR pembro+chemo | p=0.86 |
Median PFS | 46.1 mo (95%CI 39.5-NR) | PFS in PD-L1≥1%PFS in PD-L1 neg | NR (46.1-NR)28.1 mo (16.3-NR)p=0.013 |
Oligoprogression during pembro | |||
Total | 17 (24%) | ||
Locoregional | 8 | PFS oligo subgroup | 12.0 mo (9.4-18.9) |
Brain | 7 | PFS2 | 23.1 mo (20.2-NR) |
Progression post pembro | |||
Total | 20 (28%) | Median time to progression | 3.3 mo (1.0-26.3) |
Locoregional | 11 | ||
Brain | 3 | ||
Bone | 5 | ||
PD-L1≥1% | 13 | Pts with CR | 2 |
PD-L1 neg | 6 (OR 3.46, p=0.06) | Pts without CR | 18 (OR 5.06, p=0.04) |
Brain mets at diagnosis (n=18) | |||
CNS progression | 6 (33%) |
Conclusions
Pts completing two years of pembro for NSCLC in Australia had high rates of K-Ras mutation and PD-L1 expression; a significant proportion had brain metastases and treated oligoprogression. Progression rate post pembro was higher in PD-L1-negative pts and in those without complete response.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
AURORA (AUstralian Registry and biObank of thoRacic cAncers) national database. Each participating hospital in various sites throughout Australia had ethics approval to contribute to the AURORA database via their local ethics committee.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
26P - Subcutaneous trastuzumab versus intravenous trastuzumab for treatment of patients with HER2-positive breast cancer: A time, motion and cost-benefit assessment in a day care oncology unit in China
Presenter: Bei Sun
Session: Poster Display
Resources:
Abstract
27P - The biological characteristics of HER2-low in TNBC using mRNA profiling and molecular subtypes
Presenter: Asako Tsuruga
Session: Poster Display
Resources:
Abstract
28P - One-week ultra-hypofractionated partial breast RT in early breast cancer: 3DCRT vs IMRT
Presenter: Nurilla Zaynutdinov
Session: Poster Display
Resources:
Abstract
30P - Stereotactic body radiotherapy using cyberknife versus interstitial brachytherapy in accelerated partial breast irradiation on left-sided breast: A comparison of preliminary clinical result and dosimetric characteristics
Presenter: Ting-Na Wei
Session: Poster Display
Resources:
Abstract
31P - Prognostic implication of breast edema on preoperative breast MRI in breast cancer
Presenter: Ki-tae Hwang
Session: Poster Display
Resources:
Abstract
32P - Efficacy of olanzapine in the prophylaxis of delayed chemotherapy-induced nausea and vomiting in breast cancer patients receiving dose-dense AC with a steroid-sparing regimen: A single-center pilot study
Presenter: Manami Tada
Session: Poster Display
Resources:
Abstract
34P - Social support as the mediator of the association between unmet needs and happiness among women with early breast cancer
Presenter: Nithiya Sinarajoo
Session: Poster Display
Resources:
Abstract
35P - Prospective study assessing the efficacy and safety of a scalp cooling device for the prevention of alopecia in breast cancer patients undergoing (neo)adjuvant chemotherapy
Presenter: Winnie Yeo
Session: Poster Display
Resources:
Abstract
37P - To excise or not to excise: Preventive management of early breast cancer in atypical ductal hyperplasia patients
Presenter: Clarisse Hing
Session: Poster Display
Resources:
Abstract
38P - Exploring prognostic factors in patients achieving PCR after neoadjuvant therapy for triple-negative breast cancer: A retrospective study based on SEER data
Presenter: Lv Wenjie
Session: Poster Display
Resources:
Abstract